Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1958 1
1996 6
1997 5
1998 11
1999 8
2000 6
2001 11
2002 15
2003 19
2004 13
2005 4
2006 5
2007 6
2008 6
2009 5
2010 8
2011 12
2012 7
2013 7
2014 4
2015 6
2016 4
2017 5
2018 3
2019 5
2020 3
2021 4
2022 8
2023 5
2024 0

Text availability

Article attribute

Article type

Publication date

Similar articles for PMID: 14556923

187 results

Results by year

Filters applied: . Clear all
Page 1
An open randomised trial of second-line endocrine therapy in advanced breast cancer. comparison of the aromatase inhibitors letrozole and anastrozole.
Rose C, Vtoraya O, Pluzanska A, Davidson N, Gershanovich M, Thomas R, Johnson S, Caicedo JJ, Gervasio H, Manikhas G, Ben Ayed F, Burdette-Radoux S, Chaudri-Ross HA, Lang R. Rose C, et al. Eur J Cancer. 2003 Nov;39(16):2318-27. doi: 10.1016/s0959-8049(03)00630-0. Eur J Cancer. 2003. PMID: 14556923 Clinical Trial.
Exemestane versus anastrozole as front-line endocrine therapy in postmenopausal patients with hormone receptor-positive, advanced breast cancer: final results from the Spanish Breast Cancer Group 2001-03 phase 2 randomized trial.
Llombart-Cussac A, Ruiz A, Antón A, Barnadas A, Antolín S, Alés-Martínez JE, Alvarez I, Andrés R, García Saenz JA, Lao J, Carrasco E, Cámara C, Casas I, Martín M. Llombart-Cussac A, et al. Cancer. 2012 Jan 1;118(1):241-7. doi: 10.1002/cncr.26299. Epub 2011 Jun 29. Cancer. 2012. PMID: 21717449 Free article. Clinical Trial.
Anastrozole ('Arimidex') versus tamoxifen as first-line therapy in postmenopausal women with advanced breast cancer: results of the double-blind cross-over SAKK trial 21/95--a sub-study of the TARGET (Tamoxifen or 'Arimidex' Randomized Group Efficacy and Tolerability) trial.
Thürlimann B, Hess D, Köberle D, Senn I, Ballabeni P, Pagani O, Perey L, Aebi S, Rochlitz C, Goldhirsch A. Thürlimann B, et al. Breast Cancer Res Treat. 2004 Jun;85(3):247-54. doi: 10.1023/B:BREA.0000025420.78346.f9. Breast Cancer Res Treat. 2004. PMID: 15111763 Clinical Trial.
187 results